Generium ZAO

Los Angeles, USA, May 10, 2021 (GLOBE NEWSWIRE) -- Anti-CD19 Antibody Pipeline Report, 2021 Featuring TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela Bio, and others Approximately 15+ key companies are developing Anti-CD19 Antibody. The companies with their Anti-CD19 Antibody-drug candidates in the most advanced stage include Viela Bio, ADC Therapeutics, Amgen, Morphosys and Xencor. DelveInsight’s “Anti-CD19 Antibody Pipeline Insight” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Anti-CD19 Antibody pipeline landscapes. It comprises Anti-CD19 Antibody pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Anti-CD19 Antibody therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Anti-CD19 Antibody pipeline products. Some of the key takeaways of the Anti-CD19 Antibody Pipeline Report Get an overview of pipeline landscape @ Anti-CD19 Antibody Clinical Trials Analysis Anti-CD19 Antibody, a cluster of differentiation 19 (CD19), is a cell surface molecule expressed on B- lineage cells and follicular dendritic cells. CD19 comprises two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail. It functions as a positive regulator of B-cell receptor signalling in conjunction with CD21 and CD81. CD19 is expressed throughout B-cell development and plays a critical role in maintaining the balance between humoral, antigen-induced immune response and tolerance induction. Anti-CD19 Antibody Emerging Drugs Inebilizumab is a humanised monoclonal antibody designed to target and deplete CD19-expressing B cells through antibody-dependent cell-mediated cytotoxicity. Research and DevelopmentMyasthenia GravisPhase III NCT04524273: In August 2020, Viela Bio initiated a randomised, double-blind, multicenter, placebo-controlled Phase 3 study with an open-label period to assess the efficacy and safety of Inebilizumab in adults with Myasthenia Gravis. This study is a phase 3, randomised, double-blind, placebo-controlled study conducted at approximately 100 study sites. About 252 subjects (172 AChR-Ab+ and 80 MuSK-Ab+) will be enrolled. The study is estimated to get completed by December 2024 with 252 registered participants. IgG4-Related Disease Phase IIINCT04540497: In October 2020, Viela Bio initiated a Phase 3, randomised, double-blind, multicenter, and placebo-controlled study of Inebilizumab efficacy and safety in IgG4-Related Disease. This study focuses on defining the effectiveness and safety of Inebilizumab for the prevention of flare of IgG4-related disease (IgG4-RD). The study is estimated to get completed by June 2024 with 160 enrolled participants. For further information, refer to the detailed report @ Anti-CD19 Antibody Pipeline Therapeutics Scope of Anti-CD19 Antibody Pipeline Drug Insight Key Questions regarding Current Anti-CD19 Antibody Treatment Landscape and Emerging Therapies Answered in the Pipeline Report Table of Contents Get a customised pipeline report @ Anti-CD19 Antibody Drugs Pipeline Report Related Reports DelveInsight's Advanced Renal Cell Carcinoma (RCC) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight’s Global Kinase Inhibitor Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Alzheimer's disease Market Insights, Epidemiology and Market Forecast 2030 report provides an overview of disease and understanding of historical and forecasted epidemiology. DelveInsight's Anemia in CKD patients - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's ATCL Market report 2030 delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market trends in 7MM. Hidradenitis Suppurativa Market Research Report presents a detailed analysis of HS Epidemiology, Drug therapies, and pipeline for the study period from 2017-2030. About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Portfolio Management Services to understand the competencies, leverage strengths to prioritise strategic goals and understand the market’s current needs.